198,310 research outputs found
Cerebrovascular disease in highly active antiretroviral therapy-treated individuals : Incidence and risk factors
No full textThe occurrence of cerebrovascular events in patients infected by human immunodeficiency virus (HIV) has been traditionally associated with opportunistic infections and tumors, and/or advanced stages of immunosuppression. The current use in the clinical practice of antiretroviral treatment (ART) has been associated with a dramatic reduction of HIV-related mortality. Due to the increase of median age of HIV-infected subjects and to the ART-induced lipid abnormalities, an increasing incidence of vascular complications has been reported in this population. The potential contribution of these novel mechanisms should be considered and added to the classic vascular risk factors in the HIV-infected population and the cardiac abnormalities frequently observed in these patients. Large-scale epidemiological studies are needed to better define the incidence of cerebrovascular events in HIV-infected patients and the factors associated with their occurrence
Anti-HIV-1 intermittent drug intensification in HIV-1-infected patients naive for antiretrovirals
No full text
Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives
No full textSeveral 2,3-diaryl-1,3-thiazolidine-4-thione derivatives and 2,3-diaryl-1,3-thiazolidin-4-ones bearing a methyl group at C-5 position have been synthesized and tested as anti-HIV agents. The results of the in vitro tests showed that some of them proved to be effective inhibitors of HIV-1 replication
Three-dimensional alveolar bone reconstruction with a combination of recombinant human platelet-derived growth factor BB and guided bone regeneration: a case report
No full textA report of a patient who presented with severe disfigurement of the maxillary left lateral incisor and canine area following oncologic surgery is presented. The bone defect extended 20 mm from the cervical line of adjacent teeth up to and including the nasal cavity. Treatment was performed with a 1:1 ratio of autogenous bone graft (harvested from the retromolar region) and deproteinized bovine bone particles. The composite graft was hydrolyzed with recombinant human platelet-derived growth factor BB and covered with a titanium-reinforced nonresorbable membrane. Second-stage surgery was performed at 6 months, at which point the membrane was removed and two titanium dental implants were successfully placed. The elapsed time from initial surgery to definitive prosthesis placement was 14 month
Treatment interruptions in HIV-infected subjects
No full textDespite a high antiviral efficacy, the use of highly active antiretroviral therapy (HAART) in clinical practice is often impaired by the long-term toxicity of antiretroviral treatment, the increased rate of human immunodeficiency virus-1 (HIV-1) drug resistance in treated patients and the cost of therapies, so that possible interruption of HAART has to be considered as part of the current clinical practice. However, this strategy is usually followed by a rapid viral rebound with a substantial loss of CD4 T lymphocytes because the HIV suppression with HAART does not result in reconstitution of the HIV-specific immune response. Structured treatment interruption (STI) has already been investigated in HIV-infected subjects with well-controlled viral replication (initiating treatment during primary or chronic HIV infection) and in those with multiple treatment failures. A clear benefit of STI in patients with chronic infection remains controversial and these benefits are more often observed in patients starting treatment during primary HIV infection
Dr. Duane M. Jackson, Morehouse College, July 2011
No full textThis video is a conversation with Dr. Duane M. Jackson. Dr. Jackson talks about his paper, "Recall and the Serial Position Effect: The Role of Primacy and Recency on Accounting Students' Performance." Jackie Daniel, AUC Woodruff Library, is the interviewer
- …
